NEW YORK (GenomeWeb News) – Genetic Technologies this week said that it has created a new North American molecular diagnostics division, which will be led by Lewis Stuart, formerly senior VP of commercial operations at CV Therapeutics. The division will be located in the Eastern US, said Genetic Technologies, and will be responsible for launching the firm's recently acquired BrevaGen test for non-hereditary breast cancer. The BrevaGen test and certain other assets were acquired earlier this year from the now-defunct Perlegen Sciences.
Aushon Biosystems this week said it has placed its 2470 Arrayer with Phadia, an Uppsala, Sweden-based blood diagnostics firm. Phadia's Multiplexing Diagnostics division will use the 2470 in its research efforts to characterize new allergens and to discover biomarker signatures that can be used in the molecular diagnosis of allergies and autoimmune diseases.